**Table, SDC1: Adverse effects during DPA therapy**

|  |  |
| --- | --- |
| Patient | Adverse effects |
| No. 1 | arthralgia |
| No. 2 | dermatologic (d,e); fever |
| No. 4 | arthralgia; dermatologic (a,d,e);  |
| No. 5 | nephrotoxicity |
| No. 6 | oral lesions |
| No. 7 | dysarthria |
| No. 9 | allergic reaction; dermatologic (b); fever;  |
| No. 10 | hematologic toxicities; elevated ANA-titer; tremor |
| No. 11 | arthralgia; dermatologic (b);  |
| No. 12 | ulcerative coltis |
| No. 14 | allergic reaction; tremor |
| No. 15 | dermatologic (a,b,d) |
| No. 16 | dermatologic (c,d); gingival hypertrophy; breast hypertrophy |
| No. 19 | elevation of transaminases; elevated ANA-titer |
| No. 20 | dermatologic (c) |
| No. 22 | hematuria; elevation of transaminases; elevated ANA-titer |
| No. 23 | neuropathic myalgia; elevated ANA-titer |
| No. 24 | dermatologic (a,d,f) |
| No. 25 | dermatologic (f) |
| No. 26 | nephrotic syndrome; migraine; tremor |
| No. 27 | migraine |
| No. 28 | dermatologic (b) |
| No. 30 | hematologic toxicities |
| No. 31 | dermatologic (c) |

DPA = D-penicillamine; dermatologic: a= cutaneous lupus erythematosus; b=exanthema; c= hirsutism; d= pruritus ; e=urticaria; f=vitiligo;